Spots Global Cancer Trial Database for hr+
Every month we try and update this database with for hr+ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04524000 | Advanced Breast... | Alpelisib Fulvestrant | 18 Years - | Novartis | |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | NCT03874325 | Breast Cancer Hormone Recepto... | Durvalumab Anastrozole 1mg Letrozole 2.5mg Exemestane 25 M... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment | NCT06311383 | Breast Cancer | First-line Ribo... First-line endo... First-line chem... | 18 Years - | Novartis | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer | NCT05064085 | Hormone Recepto... | Cemiplimab Capecitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | NCT02894398 | Breast Cancer Hormone Recepto... Human Epidermal... | Palbociclib Letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | iOMEDICO AG | |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | NCT05645536 | Breast Cancer | TOL2506 Tamoxifen Letrozole table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 51 Years | Tolmar Inc. | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant | NCT04899349 | Breast Cancer | Alpelisib Fulvestrant Metformin XR Dapagliflozin +... Dapagliflozin | 18 Years - | Novartis | |
| Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | NCT04906395 | Breast Cancer | TOL2506 Tamoxifen Letrozole Table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 49 Years | Tolmar Inc. | |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | NCT03671330 | Breast Cancer | Ribociclib Plac... Ribociclib NSAI: Letrozole... Letrozole Goserelin | 18 Years - 60 Years | Novartis | |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | NCT05645536 | Breast Cancer | TOL2506 Tamoxifen Letrozole table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 51 Years | Tolmar Inc. | |
| Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer | NCT05064085 | Hormone Recepto... | Cemiplimab Capecitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | NCT04906395 | Breast Cancer | TOL2506 Tamoxifen Letrozole Table... Anastrozole Tab... Exemestane Tabl... | 18 Years - 49 Years | Tolmar Inc. | |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant | NCT04899349 | Breast Cancer | Alpelisib Fulvestrant Metformin XR Dapagliflozin +... Dapagliflozin | 18 Years - | Novartis | |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | NCT05549505 | Breast Cancer | ARV-471 Anastrozole Surgical resect... | 18 Years - | Arvinas Inc. | |
| Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | NCT03874325 | Breast Cancer Hormone Recepto... | Durvalumab Anastrozole 1mg Letrozole 2.5mg Exemestane 25 M... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | NCT03219476 | Breast Cancer Invasive Breast... | Anastrozole Letrozole Exemestane Tamoxifen | 18 Years - | Medical College of Wisconsin |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
